Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients

Oral administration once daily. Starting dose is 10 mg and will be escalated depending on any dose-limiting toxicities

Oral administration twice daily. Starting dose is 40mg twice daily and will be escalated depending on any dose-limiting toxicities

Oral administration of the defined MTD which shows optimal safety, PK profile, PD target inhibition and preliminary efficacy (once daily or twice daily) in different patient groups